Patents by Inventor Eric O. Long

Eric O. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD28H DOMAIN-CONTAINING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
    Publication number: 20230190800
    Abstract: Chimeric antigen receptors including (a) an antigen binding domain; (b) a transmembrane domain; and (c) an intracellular domain comprising a first intracellular signaling domain from CD28 homolog (CD28H) and a second intracellular signaling domain are provided. In some examples, the second intracellular domain is from 2B4, TCR?, Fc?R1?, or DAP12. Chimeric antigen receptors including (a) an antigen binding domain; (b) a transmembrane domain; and (c) an intracellular domain comprising a first intracellular signaling domain from CD28H, a second intracellular signaling domain from 2B4, and a third intracellular signaling domain are also provided. In some examples, the third intracellular domain is from TCR?, Fc?R1?, or DAP12. Nucleic acid molecules encoding the CARs and expression vectors including the nucleic acids are also provided. Isolated cells (such as T cells or natural killer cells) expressing the CARs and methods of treating a subject with cancer with the isolated cells are provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 22, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Eric O. Long, Xiaoxuan Zhuang
  • ANTIBODIES AND OTHER LIGANDS DIRECTED AGAINST KIR2DL4 RECEPTOR FOR PRODUCTION OF INTERFERON GAMMA
    Publication number: 20100255507
    Abstract: The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.
    Type: Application
    Filed: October 10, 2008
    Publication date: October 7, 2010
    Applicant: The Government of the United States of America, as represented by the Secretary, Dept. of Health
    Inventors: Eric O. Long, Sumati Rajagopalan
  • Antibodies and other ligands directed against KIR2DL4 receptor for production of interferon gamma
    Patent number: 7435801
    Abstract: The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: October 14, 2008
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Eric O. Long, Sumati Rajagopalan
  • Antibodies and other ligands directed against KIR2DL4 receptor for production of interferon gamma
    Publication number: 20030232051
    Abstract: The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.
    Type: Application
    Filed: April 18, 2003
    Publication date: December 18, 2003
    Inventors: Eric O. Long, Sumati Rajagopalan
  • Molecular clone of a P58 receptor protein and uses thereof
    Patent number: 5808028
    Abstract: The present invention provides a purified and isolated nucleic acid molecule encoding the p58 receptor protein. The present invention also provides vectors encoding this nucleic acid molecule, a host cell stably transformed or transfected with the vector, as well as the p58 receptor protein produced by this host cell. The present invention further provides methods for detecting nucleic acid encoding the p58 receptor as well as the p58 receptor protein in biological samples, methods for identifying a ligand capable of binding to the p58 receptor protein, and methods for screening for drugs capable of acting as agonists or antagonists to the p58 receptor protein. The present invention also provides the agonists and antagonists identified by the screening methods, as well as their use. Lastly, the present invention provides chimeric protein comprising the cytoplasmic region of a p58 receptor protein.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: September 15, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Eric O. Long, Nicolai Wagtmann
  • DNA sequences coding for the DR .beta.-chain locus of the human lymphocyte antigen complex and diagnostic typing processes and products related thereto
    Patent number: 5503976
    Abstract: DNA sequences coding for the DR-.beta.-chain locus of human lymphocyte antigen complex and diagnostic typing processes and products related thereto. DNA sequences that code for the .beta.-chain DR locus are useful in simple and efficient typing processes and products and for expression of polypeptides displaying an immunological or biological activity of the antigens of the HLA-DR .beta.-chains for use in diagnostic, preventive and therapeutic agents.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: April 2, 1996
    Assignee: BioMerieux SA
    Inventors: Bernard F. Mach, Eric O. Long, Claire T. Wake
  • DNA sequences coding for the DR .beta.-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto
    Patent number: 5169941
    Abstract: DNA sequences coding for the DR-.beta.-chain locus of human lymphocyte antigen complex and diagnostic typing processes and products related thereto. DNA sequences that code for the .beta.-chain DR locus are useful in simple and efficient typing processes and products and for expression of polypeptides displaying an immunological or biological activity of the antigens of the HLA-DR .beta.-chains for use in diagnostic, preventive and therapeutic agents.
    Type: Grant
    Filed: July 29, 1983
    Date of Patent: December 8, 1992
    Inventors: Bernard F. Mach, Eric O. Long, Claire T. Wake